Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations.
Why Is Acadia Pharmaceuticals Stock Trading Lower On Tuesday? biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Shares of ACADIA Pharmaceuticals Inc. (ACAD) are down more than 18 percent in pre-market on Tuesday at $19.71, after its schizophrenia drug candidate failed to meet the primary endpoint in late-stage study.
Acadia to end Nuplazid testing after schizophrenia trial flop and years of failed expansion efforts fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.